CELLECTAR NEW22 DL-00001 (NV4.BE)
| Previous close | 1.4000 |
| Open | 1.4400 |
| Bid | 1.3300 x N/A |
| Ask | 1.5800 x N/A |
| Day's range | 1.4400 - 1.4400 |
| 52-week range | 1.2100 - 7.1000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update. Fourth Quarter and Recent Corporate Highlights Presented preclinical data on the CLR 12120 series of targeted alpha therapies (TATs) at the 13th Annual World ADC C
- GlobeNewswire
Cellectar to Participate at Upcoming Banking Conferences
FLORHAM PARK, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced the company will participate in and be available for 1x1 meetings at the following upcoming conferences: Roth Capital Partners 35th Annual ConferenceDate: March 13, 2023Time: 8:30 – 8:55 AM ETFormat: Fireside Chat and available for 1x1 in
- GlobeNewswire
Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient
Response Achieved in Primary Central Nervous System Lymphoma for which there is no Approved TreatmentFLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that a patient with primary central nervous system lymphoma (PCNSL) enrolled in its Phase 2 CLOVER-1 Trial demonstrated a complete response
